GenomOncology announces GO Pathology Workbench in use by Emory Healthcare for Clinical Reporting
CLEVELAND, Oct. 23, 2018 /PRNewswire/ -- GenomOncology today announced that Emory Healthcare is now using GenomOncology's GO Pathology Workbench system as part of its clinical reporting process, enabling the return of clinical reports to ordering physicians more rapidly and in a comprehensive format that aids their decision making.
"Today's Molecular Pathology lab is challenged by an overwhelming amount of information that is dispersed among siloed databases and tools. This makes the interpretation of molecular data onerous for pathologists and oncologists. Our goal is to enable precision oncology by connecting disparate tools and databases and allowing data to flow end to end to aid the case workflow. The GO Pathology Workbench provides reporting that is comprehensive and actionable, thus supports decision making by oncologists," added Manuel J. Glynias, Founder and CEO of GenomOncology.
The GO Pathology Workbench utilizes the GO Knowledge Management System (GO KMS) that leverages the work of Vanderbilt University's My Cancer Genome team, led by Dr. Mia Levy. The GO KMS can match a patient's biomarkers to therapies, prognoses and Clinical Trials. This capability means that the new Emory report highlights only the relevant therapies and clinical trials.
"GenomOncology's Pathology Workbench is an important part of our solid tumor panel clinical reporting workflow, and we're also planning on using it for our new myeloid panel," said Charles Hill, MD, PhD, Director of the Molecular Diagnostics Laboratory at Emory University Hospital. "In addition, we are benefiting from GenomOncology's engaged biotechnology partnership."
About GenomOncology's GO Pathology Workbench
GenomOncology's GO Pathology Workbench for analysis and reporting is the flagship product within the GO portfolio, which includes a full suite of tools designed to enable real-time decision support at the point-of-care to accelerate precision oncology and bring about dramatic improvements in patient outcomes. The software is installed behind an institution's firewall and is configured to each laboratory's specific needs.
The GO Pathology Workbench provides a customized workflow for labs to analyze sequencing data efficiently and manage relevant molecular testing results from NGS and other test modes, including FISH, karyotyping, RT-PCR, IHC, and Array. Specifically, Emory Healthcare uses the software to evaluate for the presence of genetic alterations, and generate and sign-out clinical reports.
Integral to the GO Pathology Workbench is GenomOncology's Knowledge Management System (KMS), which not only provides direct access to gene and variant-level information derived from My Cancer Genome®, but also allows Emory Healthcare to curate additional knowledge as it is encountered in the laboratory setting.
About GenomOncology
GenomOncology enables the application of genomics in oncology to improve patient care. We have applied our expertise in genomics, technology and data integration to create solutions for cancer care providers. Our solutions are end-to-end: from the data coming out of the sequencer to the bedside where oncologists make treatment decisions. Our technology streamlines workflow and creates actionable reports for pathologists. Downstream, we integrate molecular and clinical information, providing oncologists with powerful decision-support tools that enable treatment selection, patient identification for clinical trials, and a "patients-like-mine" feature for use in difficult cases – all delivered through a real-time platform. Our solutions also enable "Big Data" analysis of aggregate data to drive research and new insights.
For more information about GenomOncology:
Teresa Fletcher
VP, Business Development
Tel: (646) 327-3932
Email: teresa@genomoncology.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/genomoncology-announces-go-pathology-workbench-in-use-by-emory-healthcare-for-clinical-reporting-300735440.html
SOURCE GenomOncology